18 completed, 3 active not recruiting, 3 terminated, 2 unknown. 27 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Completed 18, Active not recruiting 3, Terminated 3, Unknown 2, Withdrawn 1 |
| Phase 2 | 7 | Completed 4, Terminated 2, Unknown 1 |
Follow Interferon alpha-2: new trials by email Literature Review of Interferon alpha-2 trials Research Report on Interferon alpha-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis Interferon Alfa-2A, Cyclosporine Pill - Behçet Disease, Uveitis | Phase 3 | Completed | Peking Union Medical College Hospital | 28 | 2017-06-30 | 2021-02-23 |
| Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Biospecimen Collection, Computed Tomography, Ipilimumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1301 | 2015-11-10 | 2026-10-01 |
| Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b - Melanoma of Unknown Primary, Recurrent Melanoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1673 | 2011-06-17 | 2026-10-22 |
| To Study the Efficacy and Safety of Renessans in Chronic HCV Patients RENESSANS , INTERFERON ALPHA 2b, Ribavirin, Interferon Alfa-2b AND RIBAVIRIN, RENESSANS - Hepatitis C, Chronic | Phase 3 | Unknown | MTI Medical Private Limited, Pakistan | 90 | 2010-06-01 | 2011-11-22 |
| Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients CSF470 vaccine, BCG, Molgramostim, interferon alpha 2b - Cutaneous Melanoma | Phase 2 / Phase 3 | Unknown | Laboratorio Pablo Cassara S.R.L. | 108 | 2009-04-01 | 2015-09-02 |
| Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate - Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 427 | 2007-12-01 | 2026-10-22 |
| Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders interferon alfa-2b - Chronic Hepatitis C | Phase 2 / Phase 3 | Completed | Foundation for Liver Research | 30 | 2007-07-01 | 2011-03-11 |
| Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB) Cyclosporin A, Interferon-alpha2a - Behcet's Disease, Panuveitis | Phase 3 | Completed | University Hospital Tuebingen | 37 | 2004-11-01 | 2018-05-17 |
| Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB pegylated interferon-alpha-2a, interferon-alpha-2a - Melanoma | Phase 3 | Completed | University Hospital Tuebingen | 901 | 2004-10-01 | 2017-05-03 |
| SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma Interferon-alfa, SU011248 - Carcinoma, Renal Cell | Phase 3 | Completed | Pfizer | 750 | 2004-08-01 | 2010-01-26 |
| A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Bevacizumab [Avastin], Interferon alfa 2a [Roferon], Placebo - Renal Cell Cancer | Phase 3 | Completed | Hoffmann-La Roche | 649 | 2004-06-01 | 2016-06-23 |
| A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies Pegylated Interferon Alfa-2a, Recombinant Interferon Alfa 2a - Chronic Myelogenous Leukemia, Malignant Melanoma | Phase 2 / Phase 3 | Completed | Hoffmann-La Roche | 9 | 2004-01-01 | 2017-01-09 |
| High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF) - Leukemia, Myeloid, Chronic | Phase 3 | Completed | M.D. Anderson Cancer Center | 94 | 2003-04-01 | 2016-05-11 |
| High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV Peginterferon alfa-2a, Interferon alfa-2a, Ribavirin - Hepatitis C | Phase 3 | Completed | Foundation for Liver Research | 33 | 2003-02-01 | 2021-09-01 |
| A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma rituximab, interferon-a-2a - Lymphoma | Phase 3 | Completed | Hoffmann-La Roche | 313 | 2002-10-01 | 2014-09-08 |
| Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma Dacarbazine, Fotemustine, Interferon Alfa-2b - Malignant Melanoma, Recurrent Melanoma | Phase 3 | Completed | National Cancer Institute, Naples | 269 | 2002-04-01 | 2023-04-11 |
| Structured Treatment Interruptions With or Without Pegylated Interferon Alpha for HIV-Infected Patients After Prolonged Viral Suppression Interferon alfa-2b, Structured treatment interruptions - HIV Infections | Phase 3 | Terminated | French National Agency for Research on AIDS and Viral Hepatitis | 200 | 2001-12-01 | 2005-08-16 |
| High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma interferon alfa-2b, observation - Melanoma (Skin) | Phase 3 | Completed | ECOG-ACRIN Cancer Research Group | 1150 | 1999-03-25 | 2026-09-29 |
| Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) Pegylated interferon alfa-2b, Interferon alfa-2b - Chronic Myelogenous Leukemia | Phase 2 / Phase 3 | Terminated | Merck Sharp & Dohme LLC | 344 | 1998-10-22 | 2019-08-12 |
| Interferon Alpha 2b Plus Ribavirin for Chronic Hepatitis B interferon alpha 2b plus ribavirin, interferon alpha 2b plus placebo - Chronic Hepatitis B | Phase 2 / Phase 3 | Completed | National Taiwan University Hospital | 120 | 1998-10-01 | 2006-01-12 |
Showing 20 of 27. Sign in to see all of them.
Melanoma (9) · Carcinoma, Renal Cell (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Behcet Syndrome (2) · Hepatitis C (2) · Hepatitis C, Chronic (2) · Burns (1) · Cicatrix, Hypertrophic (1) · HIV Infections (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Kidney Neoplasms (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma (1) · Neuroendocrine Tumors (1)
Hoffmann-La Roche (3) · Merck Sharp & Dohme LLC (3) · National Cancer Institute (NCI) (3) · Foundation for Liver Research (2) · M.D. Anderson Cancer Center (2) · University Hospital Tuebingen (2) · Centre Leon Berard (1) · ECOG-ACRIN Cancer Research Group (1) · French Innovative Leukemia Organisation (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Gruppo Oncologico Italiano di Ricerca Clinica (1) · Laboratorio Pablo Cassara S.R.L. (1) · MTI Medical Private Limited, Pakistan (1) · National Cancer Institute, Naples (1) · National Taiwan University Hospital (1)
United States (7) · Canada (6) · France (4) · Germany (4) · Australia (3) · Italy (3) · Netherlands (3) · Russia (3) · Spain (3) · Norway (2) · Poland (2) · South Africa (2) · United Kingdom (2) · Argentina (1) · Belgium (1)
Agop Y. Bedikian, MD (1) · Ahmad Tarhini (1) · Alberto S. Pappo, MD (1) · Antonio Daponte, M.D. (1) · Carlo Buzio, Medicine (1) · Claus Garbe, MD (1) · Dominique Costagliola (1) · Edward E Tredget, MD MSc FRCSC (1) · Hubert Pehamberger, MD (1) · Ina Koetter, MD (1) · James C Yao (1)
PMID 15256423, PMID 17215529, PMID 17932908, PMID 19430405, PMID 20104222, PMID 23402397, PMID 23620574, PMID 25304727, PMID 25577718, PMID 25649350, PMID 25686644, PMID 27238653, PMID 27287206, PMID 28384065, PMID 28410911, PMID 28620382, PMID 28835440, PMID 29774030, PMID 29853320, PMID 30885996, PMID 35659704, PMID 36029412, PMID 36416836, PMID 37146227
2004 (2), U10CA180888 (2), P30CA016672 (1), P50CA121973 (1), U10CA021115 (1), U10CA023318 (1), U10CA032102 (1), U10CA180820 (1), U24CA196172 (1)